Novel strategies for pharmacotherapy of depression

被引：47

作者：

Maubach, KA

Rupniak, NMJ

Kramer, MS

Hill, RG

机构：

[1] Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England

[2] Merck Res Labs, W Point, PA 19456 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 1999年 / 3卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(99)80070-2

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Modulating monoamine activity as a therapeutic strategy continues to dominate antidepressant research, with a recent emphasis on agents with multiple targets, including combined serotonin/noradrenaline re-uptake inhibitors and numerous serotonin receptor ligands. An important new development has been the emergence of potential novel mechanisms of action, notably modulation of the activity of neuropeptides substance P and corticotrophin-releasing factor, and the intracellular messenger cyclic adenosine monophosphate. Efforts in this area have recently been rewarded by the demonstration of antidepressant efficacy of the substance P receptor antagonist MK-0869.

引用

页码：481 / 488

页数：8

共 65 条

[41]

Masugi M, 1999, J NEUROSCI, V19, P955

[42] The role of corticotropin releasing factor in depressive illness: A critical review [J].